GB1139991A - Stabilized enzyme composition - Google Patents

Stabilized enzyme composition

Info

Publication number
GB1139991A
GB1139991A GB3222266A GB3222266A GB1139991A GB 1139991 A GB1139991 A GB 1139991A GB 3222266 A GB3222266 A GB 3222266A GB 3222266 A GB3222266 A GB 3222266A GB 1139991 A GB1139991 A GB 1139991A
Authority
GB
United Kingdom
Prior art keywords
july
enzymes
excipients
enzyme composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3222266A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Armour Pharmaceutical Co
Original Assignee
Armour Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armour Pharmaceutical Co filed Critical Armour Pharmaceutical Co
Publication of GB1139991A publication Critical patent/GB1139991A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

1,139,991. Oral enzyme compositions. ARMOUR PHARMACEUTICAL CO. 18 July, 1966 [19 July, 1965], No. 32222/66. Heading A5B. A pharmaceutical composition for oral administration of enzymes comprises as the only active ingredients other than excipients at least one pancreatic enzyme and a buffer to maintain the pH of the gastric fluid between 4 and 7, which is one or more of calcium carbonate, magnesium carbonate, sodium bicabonate, sodium citrate, disodium phosphate, or dicalcium phosphate. The composition may contain inert excipients such as polyvinylpyrrolidone, magnesium stearate and lactose and may be in the form of tablets, capsules, or a powder. The enzymes may be trypsin or chymotrypsin or naturally accurring mixtures thereof, such as pancreatin.
GB3222266A 1965-07-19 1966-07-18 Stabilized enzyme composition Expired GB1139991A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47279165A 1965-07-19 1965-07-19

Publications (1)

Publication Number Publication Date
GB1139991A true GB1139991A (en) 1969-01-15

Family

ID=23876960

Family Applications (1)

Application Number Title Priority Date Filing Date
GB3222266A Expired GB1139991A (en) 1965-07-19 1966-07-18 Stabilized enzyme composition

Country Status (1)

Country Link
GB (1) GB1139991A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2121685A (en) * 1982-04-30 1984-01-04 Kaken Pharma Co Ltd Protease compositions for treating blood lipids abnormality and arteriosclerosis
FR2603804A1 (en) * 1986-09-17 1988-03-18 Jouveinal Sa LIPASES AND LIPASIC EXTRACTS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
WO2006024638A2 (en) * 2004-08-31 2006-03-09 Aristocon Verwaltungs-Gmbh Peroral dosage forms to achieve a sustained-release effect after medicament dosage with a meal

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051262A (en) * 1979-12-07 1991-09-24 Elan Corp., P.L.C. Processes for the preparation of delayed action and programmed release pharmaceutical forms and medicaments obtained thereby
GB2121685A (en) * 1982-04-30 1984-01-04 Kaken Pharma Co Ltd Protease compositions for treating blood lipids abnormality and arteriosclerosis
FR2603804A1 (en) * 1986-09-17 1988-03-18 Jouveinal Sa LIPASES AND LIPASIC EXTRACTS, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS
EP0261016A1 (en) * 1986-09-17 1988-03-23 Jouveinal S.A. Lipase and lipasic extracts, process of preparation and therapeutic use
WO2006024638A2 (en) * 2004-08-31 2006-03-09 Aristocon Verwaltungs-Gmbh Peroral dosage forms to achieve a sustained-release effect after medicament dosage with a meal
WO2006024638A3 (en) * 2004-08-31 2007-04-05 Aristocon Verwaltungs Gmbh Peroral dosage forms to achieve a sustained-release effect after medicament dosage with a meal
EA013429B1 (en) * 2004-08-31 2010-04-30 Аристокон Фервальтунгс - Гмбх Peroral dosage forms to achieve a sustained-release effect after taking active pharmaceutical ingredient (api) together with a meal

Similar Documents

Publication Publication Date Title
ES8308698A1 (en) Topical pharmaceutical compositions
GB1418208A (en) Pharmaceutical compositions
KR870005647A (en) Stabilized Human Tissue Plasminogen Activator Composition
EP0130779A3 (en) Pharmaceutical composition suitable for intestinal administration
GB1227534A (en)
MY102929A (en) Aqueous pharmaceutical formulations of piroxicam monohydrate
EP0237241A3 (en) Calcium supplement compressed tablets
GB1139991A (en) Stabilized enzyme composition
MY104937A (en) Cephalosporin derivatives and processes for their preparation
US3803304A (en) Orally administratable pancreatic enzymes and methods of using same
GB1403900A (en) Pharmaceutical composition
CA2255064A1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
GB1191246A (en) Vitamin-containing Preparations
HU912742D0 (en) T-pa pro-stabilization
GB1327560A (en) Effervescent pharmaceutical preparations
GB1251398A (en)
GB1118606A (en) Compositions for the treatment of haemorrhoids
GB1291281A (en) Improvements in pharmaceutical compositions
GB1321419A (en) Pharmaceutical composition
GB1353834A (en) Benzenesulphonamides
GB1291282A (en) Improvements in pharmaceutical compositions
IE36780L (en) Pharmaceutical preparations
GB1153206A (en) Preparation of Substituted alpha-Phenylalkanoic Acids
GB1137540A (en) Improvements relating to the treatment of hypocalcaemia
GB1389187A (en) Carbonated 1-lysine